ResoTher Pharma wins Innobooster award

ResoTher Pharma is pleased to announce that the company has been awarded an Innobooster grant in the amount of DKK 4.900.000 from the Danish Innovation Foundation. The award will fund the continued development of RTP-026, a novel peptide FPR2 agonist.  RTP-026 has...

read more

ResoTher Pharma featured at StartUp Spotlight BioEurope Spring

ResoTher Pharma has been selected as one of the up-and-coming biotech companies to watch and will be featured at the StartUp Spotligt at this years BioEurope Spring convention on March 26th, 2019. We are pleased with the recognition and look forward to a productive...

read more

Joel Scherer, MD joins Scientific Advisory Board

ResoTher Pharma management is pleased to announce that Joel Scherer, MD has joined the company´s Scientific Advisory Board. Dr. Scherer brings considerable drug development and cardiology expertise from his former roles as Chief Medical Officer, Managing Director at...

read more

Kirsten Drejer steps up as Chairwoman of ResoTher Pharma

Kirsten Drejer, PhD takes on the role as Chairwoman of the Board of ResoTher Pharma following a unanimous vote at the company´s general assembly. “We are extremely pleased with the collaboration with Kirsten, who has a wealth of experience to contribute to a company...

read more

Thomas Engstrøm, MD joins Scientific Advisory Board

The management of ResoTher Pharma is pleased to announce that consulting cardiologist and Professor Thomas Engstrøm, MD joins the company´s scientific advisory board as an expert clinical advisor. Dr. Engstrøm is an expert in the diagnosis and treatment of Myocardial...

read more

Kirsten Drejer joins Board of Directors

Jeppe Øvlesen, Chairman of ResoTher Pharma, is pleased to announce that biotech veteran Kirsten Drejer, PhD joins the Board of Directors effective immediately. Dr. Drejer brings with her significant leadership and company building experience from her many years as...

read more